I0782
Imazodan
≥99% (HPLC)
别名:
4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinone, Cl 914
方案
≥99% (HPLC)
颜色
yellow, powder
溶解性
DMSO: 50 mg/mL, clear, yellow
SMILES字符串
O=C1CCC(=NN1)c2ccc(cc2)-n3ccnc3
InChI
1S/C13H12N4O/c18-13-6-5-12(15-16-13)10-1-3-11(4-2-10)17-8-7-14-9-17/h1-4,7-9H,5-6H2,(H,16,18)
InChI key
VXMYWVMXSWJFCV-UHFFFAOYSA-N
基因信息
human ... PDE3A(5139)
rat ... Pde3a(50678)
生化/生理作用
Selective phoshodiesterase III (PDE3) inhibitor.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
C P Nielson et al.
The Journal of allergy and clinical immunology, 86(5), 801-808 (1990-11-01)
Modulation of the human polymorphonuclear leukocyte (PMN) respiratory burst by selective cyclic 3',5' adenosine monophosphate (cAMP) phosphodiesterase (PDE) inhibitors was studied with respect to PDE isozyme characteristics. Zaprinast, an inhibitor of a cyclic guanosine monophosphate (cGMP)-specific PDE (PDE I), at
R E Weishaar et al.
Journal of cyclic nucleotide and protein phosphorylation research, 10(6), 551-564 (1985-01-01)
In the present study, the inhibitory effects of CI-914, a novel cardiotonic agent, as well as other recently identified positive inotropic agents and reference phosphodiesterase (PDE) inhibitors on the different molecular forms of cardiac PDE were examined, and correlated with
I Sircar et al.
Journal of medicinal chemistry, 30(10), 1724-1728 (1987-10-01)
A series of 2,4-dihydro-5-[4-(1H-imidazol-1-yl)phenyl]-3H-pyrazol-3-ones was synthesized and evaluated for positive inotropic activity. Only compounds with two small alkyl groups at C-4 showed significant activity. The structure-activity relationships for optimal inotropic activity are presented and compared with those of the 4,5-dihydro-3(2H)-pyridazinone
S Terris et al.
The American journal of cardiology, 58(7), 596-600 (1986-09-15)
The hemodynamic effects of CI-914, a phosphodiesterase inhibitor, were studied in 12 patients with left ventricular (LV) dysfunction who were undergoing diagnostic cardiac catheterization. CI-914 was infused intravenously at a rate of 0.8 to 7.0 micrograms/kg/min for 30 to 60
A D Goldberg et al.
The American journal of cardiology, 68(6), 631-636 (1991-09-01)
A 12-week, multicenter, double-blind, randomized, placebo-controlled trial of imazodan, a type III phosphodiesterase inhibitor, was conducted in 147 patients with congestive heart failure to determine clinical efficacy and safety. Patients were randomized to placebo or 2, 5 or 10 mg
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持